All the events here are relevant to people working in dementia research. If you would like to add your own you can submit an event
- This event has passed.
Amyloid & Tau in Alzheimer’s: Insights into Disease Progression
June 26 @ 3:00 pm - 4:00 pm
Join us for an engaging session with Dr Niklas Mattsson-Carlgren, Lund University, to explore how Alzheimer’s disease (AD) may be considered an amyloid-driven tauopathy and implications for the future AD landscape.
Dr Mattsson-Carlgren will examine the relationship between amyloid and tau pathology, including biomarker progression in AD, biological diagnosis, Braak staging, and the correlation between pathology and clinical progression.
Don’t miss the interactive Q&A session moderated by Dr Holly Brothers from Biogen, for your opportunity to join the thought-provoking discussion!
Topics:
- Exploring the pathology of the AD continuum
- Deep dive into tau clinico-pathological staging
- Moving toward a biological definition of AD
- Future directions in AD research
Learning Objectives:
- Explore biomarker progression along the Alzheimer’s disease (AD) continuum, including biological diagnosis, Braak staging, and the correlation between pathology and clinical progression.
- Evaluate the relationship between amyloid and tau pathologies, and how AD may be considered an amyloid-driven tauopathy.
- Identify key evidence gaps in the understanding of amyloid-tau dynamics and future implications for biomarker development.
This webinar is intended for healthcare professionals only.
This webinar has been organised and funded by Biogen, in partnership with AD/PD™ Education on UNLOK. Dr. Mattsson-Carlgren has been compensated by Biogen for his participation in this program.
To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform from Biogen: https://knowtau.com/en/
Veeva ID: Biogen-265000. Date of preparation: June 2025